All Oncology News

In a phase 2 study, adding venetoclax to ibrutinib rendered BTK C481X resistance mutations undetectable in patients with CLL.

Both the reactive and proactive ibrutinib dose-adjustment cohorts of the phase 2 TAILOR study met the primary ORR end point in previously untreated CLL.

Afami-cel received full FDA approval for unresectable or metastatic synovial sarcoma after prior chemotherapy.

PFS was improved only numerically with the use of maintenance dostarlimab vs observation after chemoradiation in high-risk locally advanced cervical cancer.

Eleven Western New York organizations received funding to advance cancer prevention and early detection.

China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.

The STELLAR-303 trial met its OS end point with the zanzalintinib regimen in the ITT population but failed to show the same benefit in the NLM subgroup.

Callisia N. Clarke, MD, MS, FACS, FSSO, discusses how earlier alignment between surgeons and medical oncologists on systemic therapy use allows more patients to undergo resection.

The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.

Public libraries will play a role in developing essential reading skills, improving financial literacy, and fostering critical thinking.

Six-year GARNET data show durable responses with dostarlimab in dMMR/MSI-H endometrial cancer.

The FDA accepted for review a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in LBCL, a BLA for ozekibart in chondrosarcoma, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Yale Cancer Center has appointed Ian E. Krop, MD, PhD, as Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs.

Neoadjuvant nivolumab yielded a 68.2% clinical complete response rate in patients with resectable mismatch repair–deficient endometrial cancer.

Patients with metastatic breast cancer achieving a CR/deep PR with frontline T-DXd/pertuzumab had the most durable PFS outcomes in DESTINY-Breast09.

Jonathan Trent, MD, discusses how proactive AE management, dose individualization, and liquid TKI formulations could improve treatment adherence and outcomes in GIST.

Starting TTFields with chemoradiotherapy did not significantly improve OS vs using TTFields in the maintenance phase in newly diagnosed glioblastoma.

The CDK4/6 inhibitor and aromatase inhibitor combination produced a 32% ORR and 48% clinical benefit rate at 6 months.

Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.

Despite a higher response rate with the combination, the phase 2 MIROVA/AGO-OVAR 2.34 trial did not meet its primary PFS end point over chemotherapy.

Updated data from the phase 2 COLIBRI-1 trial suggest that immune microenvironment status at baseline and following ICB induction may predict long-term survival.

The FDA has accepted a sBLA for subcutaneous mosunetuzumab plus polatuzumab vedotin in R/R LBCL.

Mayo Clinic researchers are advancing brain tumor care through molecular profiling, improved diagnostics for younger patients, new drug delivery methods, and emerging immunotherapies.

Lung cancer experts convened at an OncLive® Scientific Interchange and Workshop to discuss treatment sequencing in HER2+ NSCLC.

Real-world data showed zanubrutinib was associated with longer time to treatment discontinuation and higher persistence vs acalabrutinib or ibrutinib in first-line CLL.

Trastuzumab pamirtecan produced durable responses and encouraging survival in HER2-expressing endometrial cancer after prior therapy.

The B7-H4–targeted antibody-drug conjugate produced confirmed response rates of 62% in PROC and 67% in endometrial cancer at the doses selected for phase 3 development.

Alicia Morgans, MD, MPH, discusses findings from ARACOG trial of the cognitive effects of darolutamide vs enzalutamide in prostate cancer.

Bulumtatug fuvedotin produced a confirmed ORR of 32.08% and a DCR of 81.13% in recurrent or metastatic cervical cancer, with no treatment-related deaths.